In OS, SIR-associated mutations are preferentially located in key cancer driver genes, including TP53, RB1, MECOM, and PTPRD, and show associations with specific clinical subtypes, mutational signatures, and oncogenic pathways. The gene discussed is TP53; the disease is cancer.